Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1846-1852

  Oitate, Masataka ^a   Hirota, Takashi ^a   Murai, Takahiro ^a   Miura, Shin Ichi ^a   Ikeda, Toshihiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ETHOXYPHENYL) 4 METHYL 1 (4 SULFAMOYLPHENYL) 1H PYRROLE; 3 AMINOPROPIONITRILE; ALLYSINE; BENZALDEHYDE; CARBON 14; CELECOXIB; CS 706; CYCLOOXYGENASE 2 INHIBITOR; ELASTIN; ETORICOXIB; HYDRALAZINE; ORGANIC SOLVENT; PENICILLAMINE; PROTEINASE; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COVALENT BOND; CROSS LINKING; DATA ANALYSIS; DRUG BINDING; DRUG STRUCTURE; ELASTIC FIBER; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOACTIVITY; RAT;

2-AMINOADIPIC ACID; AGED; ALDEHYDES; ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; CELL LINE; CYCLOOXYGENASE 2 INHIBITORS; ELASTIN; FEMALE; HUMANS; LACTONES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

RATTUS;

EID: 34748833728     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016121     Document Type: Article

References (25)

1. Aldington S, Shirtcliffe P, Weatherall M, and Beasley R (2005) Systematic review and metaanalysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 118:U1684.
2. Andrews EJ, White WJ, and Bullock LP (1975) Spontaneous aortic aneurysms in blotchy mice. Am J Pathol 78:199-210.
3. Davies NM, Teng XW, and Skjodt NM (2003) Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 42:545-556.
4. Deshmukh K and Nimni ME (1969) A defect in the intramolecular and intermolecular crosslinking of collagen caused by penicillamine. II. Functional groups involved in the interaction process. J Biol Chem 244:1787-1795.
5. Eyre DR, Paz MA, and Gallop PM (1984) Cross-linking in collagen and elastin. Annu Rev Biochem 53:717-748.
6. Fredy J, Diggins Jr DA, and Morrill GB (2005) Blood pressure in Native Americans switched from celecoxib to rofecoxib. Ann Pharmacother 39:797-802.
7. Gallop PM and Paz MA (1975) Posttranslational protein modifications, with special attention to collagen and elastin. Physiol Rev 55:418-487.
8. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, and Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested casecontrol study. Lancet 365:475-481.
9. Grant RA (1967) Content and distribution of aortic collagen, elastin and carbohydrate in different species. J Atheroscler Res 7:463-472.
10. Hashimoto K, McEvoy B, and Belcher R (1981) Ultrastructure of penicillamine-induced skin lesions. J Am Acad Dermatol 4:300-315.
11. Herd K and Orbison JL (1966) Lathyrism in the fetal rat. Evidence for impairment of elastin formation. Arch Pathol 81:60-66.
12. Howard-Lock HE, Lock CJ, Mewa A, and Kean WF (1986) D-Penicillamine: chemistry and clinical use in rheumatic disease. Semin Arthritis Rheum 15:261-281.
13. Junker P, Helin G, Jensen BA, Oxlund H, and Lorenzen I (1982) D-Penicillamine-induced angiopathy in rats. Changes in aortic collagen, glycosaminoglycans, DNA and RNA in rats treated with D-penicillamine. Atherosclerosis 45:17-31.
14. Light N, Meyrick ThomasRH, Stephens A, Kirby JD, Fryer PR, and Avery NC (1986) Collagen and elastin changes in D-penicillamine-induced pseudoxanthoma elasticum-like skin. Br J Dermatol 114:381-388.
15. Maroudas A, Palla G, and Gilav E (1992) Racemization of aspartic acid in human articular cartilage. Connect Tissue Res 28:161-169.
16. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96:272-277.
17. Numata Y, Takei T, and Hayakawa T (1981) Hydralazine as an inhibitor of lysyl oxidase activity. Biochem Pharmacol 30:3125-3126.
18. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, and Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081-1091.
19. 14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos 34:1417-1422.
20. Oitate M, Hirota T, Takahashi M, Murai T, Miura S, Senoo A, Hosokawa T, Oonishi T, and Ikeda T (2007) Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J Pharmacol Exp Ther 320:1195-1203.
21. Pinnell SR and Martin GR (1968) The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci U S A 61:708-716.
22. Pinnell SR, Martin GR, and Miller EJ (1968) Desmosine biosynthesis: nature of inhibition by D-penicillamine. Science 161:475-476.
23. Tang SS, Trackman PC, and Kagan HM (1983) Reaction of aortic lysyl oxidase with β-aminopropionitrile. J Biol Chem 258:4331-4338.
24. Vrhovski B and Weiss AS (1998) Biochemistry of tropoelastin. Eur J Biochem 258:1-18.
25. Yoshikawa H, Wang S, Seo H, Kurotaki T, Ueki H, and Yoshikawa T (2001) Ultrastructure of aortic elastic fibers in copper-deficient Sika deer (Cervus nippon Temminck). J Vet Med Sci 63:163-165.